...product has been developed to significantly increa...oteins. Stability is increased at room temperatur.... This product is subjected to 0.2 micron filtrat...lation insures consistently high levels of activit...
Corning brand cover glass squares, 0.16 to 0.19mm thick from Sigma-Aldrich
...uropean Collection of Cell Cultures (ECACC) has be...y, academia and government institutes for over sev...troduce candidates to cell culture and a Level II ... as planning and management of a cell culture labo...
DU 530 Life Science UV/Visible Spectrophotometers from Beckman Coulter
Biology Products:(Date:11/24/2009)... , REYKJAVIK, Iceland, Novemb...nc. (Nasdaq: DCGN ) today announced the approval o...uptcy Court for the District of Delaware,(the "Ban...y petition for,relief under Chapter 11 of the Unit...t. , The orders issued by the Bankruptcy ...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia...Food & Drug Administration (SFDA) has approved...r its oral insulin project,(Nodlin), an innovative...pproval allows Biolaxy to initiate its first phase...er characteristic of high blood glucose and poor,m...
(Date:11/24/2009)... , , Primary efficacy endpoint has been me...t endometrial cancer, , QUEBEC CITY, Nov. 24 ...SDAQ: AEZS ; TSX: AEZ) (the "Company"), a global ...rapy and oncology, today announced positive effica...otoxic peptide conjugate, AEZS-108 (formerly AN-15...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-Fi...ARNA ) announced today that the company is sched...ealth Care Conference on December 1, 2009 at 11:30... New York Palace Hotel in New York City. Jack Lief...s scheduled to provide an overview of the company,...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3